Transcription Factor DLX5 As a New Target for Promising Antitumor Agents

RA Timakhov; PO Fedichev; AA Vinnik; JR Testa; OO Favorova

doi:10.32607/20758251-2011-3-3-47-51

Transcription Factor DLX5 As a New Target for Promising Antitumor Agents

RA Timakhov, PO Fedichev, AA Vinnik, JR Testa, OO Favorova

Cancer Prevention and Control (CPC)

Research output: Contribution to journal › Article › peer-review

Abstract

The crystal structure of the human transcription factor DLX5 has been used for the screening of a library consisting of 10(6 )compounds by the molecular docking technique.In vitro testsof the 14 top-rated ligands showed that compound Q12 displays the best ability to inhibit the proliferation ofDlx5 positive mouse lymphoma cells, which correlates with the down-regulation ofc-mycexpression. Compound Q12 has low toxicity on normal human ovarian epithelial cells and mouse lymphoma cells with absent expression ofDlx5, and can be used for further chemical optimization and for the development of novel, highly efficient cancer treatments.

Original language	American English
Pages (from-to)	47-51
Number of pages	5
Journal	Acta Naturae
Volume	3
Issue number	3
DOIs	https://doi.org/10.32607/20758251-2011-3-3-47-51
State	Published - Jul 2011

Keywords

DLX5
Cancer
Molecular docking
Small molecules
Transcription factor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.32607/20758251-2011-3-3-47-51

Cite this

@article{3f224dd61b1c430089c922e8dc527e31,

title = "Transcription Factor DLX5 As a New Target for Promising Antitumor Agents",

abstract = "The crystal structure of the human transcription factor DLX5 has been used for the screening of a library consisting of 10(6 )compounds by the molecular docking technique.In vitro testsof the 14 top-rated ligands showed that compound Q12 displays the best ability to inhibit the proliferation ofDlx5 positive mouse lymphoma cells, which correlates with the down-regulation ofc-mycexpression. Compound Q12 has low toxicity on normal human ovarian epithelial cells and mouse lymphoma cells with absent expression ofDlx5, and can be used for further chemical optimization and for the development of novel, highly efficient cancer treatments.",

keywords = "DLX5, Cancer, Molecular docking, Small molecules, Transcription factor",

author = "RA Timakhov and PO Fedichev and AA Vinnik and JR Testa and OO Favorova",

year = "2011",

month = jul,

doi = "10.32607/20758251-2011-3-3-47-51",

language = "American English",

volume = "3",

pages = "47--51",

journal = "Acta Naturae",

issn = "2075-8251",

publisher = "Acta Naturae",

number = "3",

}

TY - JOUR

T1 - Transcription Factor DLX5 As a New Target for Promising Antitumor Agents

AU - Timakhov, RA

AU - Fedichev, PO

AU - Vinnik, AA

AU - Testa, JR

AU - Favorova, OO

PY - 2011/7

Y1 - 2011/7

N2 - The crystal structure of the human transcription factor DLX5 has been used for the screening of a library consisting of 10(6 )compounds by the molecular docking technique.In vitro testsof the 14 top-rated ligands showed that compound Q12 displays the best ability to inhibit the proliferation ofDlx5 positive mouse lymphoma cells, which correlates with the down-regulation ofc-mycexpression. Compound Q12 has low toxicity on normal human ovarian epithelial cells and mouse lymphoma cells with absent expression ofDlx5, and can be used for further chemical optimization and for the development of novel, highly efficient cancer treatments.

AB - The crystal structure of the human transcription factor DLX5 has been used for the screening of a library consisting of 10(6 )compounds by the molecular docking technique.In vitro testsof the 14 top-rated ligands showed that compound Q12 displays the best ability to inhibit the proliferation ofDlx5 positive mouse lymphoma cells, which correlates with the down-regulation ofc-mycexpression. Compound Q12 has low toxicity on normal human ovarian epithelial cells and mouse lymphoma cells with absent expression ofDlx5, and can be used for further chemical optimization and for the development of novel, highly efficient cancer treatments.

KW - DLX5

KW - Cancer

KW - Molecular docking

KW - Small molecules

KW - Transcription factor

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000309952000006&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.32607/20758251-2011-3-3-47-51

DO - 10.32607/20758251-2011-3-3-47-51

M3 - Article

C2 - 22649693

SN - 2075-8251

VL - 3

SP - 47

EP - 51

JO - Acta Naturae

JF - Acta Naturae

IS - 3

ER -

Transcription Factor DLX5 As a New Target for Promising Antitumor Agents

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this